CLOV Stock Forecast & Price Target

Clover Health Investments Corp has demonstrated robust growth, reporting a 53% year-over-year increase in Medicare Advantage membership during the annual enrollment period, reaching approximately 153,000 members. The company anticipates significant revenue improvements, projecting over $70 per member per month in new member revenue, bolstered by a 4-star plan rating and favorable CMS MA rate updates for 2026. Furthermore, the adoption of Clover Assistant is expected to enhance medical cost ratios and improve unit economics as the company's cohort matures, which bodes well for long-term profitability.

Clover Health Investments Corp. faces significant challenges that negatively affect its stock outlook, particularly surrounding its potential inability to maintain a 4-Star rating, which could lead to adverse adjustments in medical loss ratio (MLR) expectations and ultimately impact earnings forecasts. Despite posting a positive adjusted EBITDA of $22.6 million amid a 33% growth in average Medicare Advantage membership, the forecast for 2026 indicates potential declines in gross profit margins due to new member dilution. Furthermore, increased regulatory scrutiny, adverse-selection risks from larger peers, and uncertainties surrounding key factors such as Medicare Advantage trends and risk scoring contribute to a cautious sentiment regarding the company's future performance.